0001209191-21-023645.txt : 20210330 0001209191-21-023645.hdr.sgml : 20210330 20210330200708 ACCESSION NUMBER: 0001209191-21-023645 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210326 FILED AS OF DATE: 20210330 DATE AS OF CHANGE: 20210330 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Rubino Stephen CENTRAL INDEX KEY: 0001849075 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-51531 FILM NUMBER: 21789225 MAIL ADDRESS: STREET 1: C/O VIRACTA THERAPEUTICS, INC. STREET 2: 2533 SOUTH COAST HWY., STE. 210 CITY: CARDIFF STATE: CA ZIP: 92007 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Viracta Therapeutics, Inc. CENTRAL INDEX KEY: 0001061027 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943295878 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2533 S COAST HWY 101 STREET 2: SUITE 210 CITY: CARDIFF STATE: CA ZIP: 92007 BUSINESS PHONE: 858-400-8470 MAIL ADDRESS: STREET 1: 2533 S COAST HWY 101 STREET 2: SUITE 210 CITY: CARDIFF STATE: CA ZIP: 92007 FORMER COMPANY: FORMER CONFORMED NAME: MOSAIC PHARMACEUTICALS INC DATE OF NAME CHANGE: 19980709 FORMER COMPANY: FORMER CONFORMED NAME: SUNESIS PHARMACEUTICALS INC DATE OF NAME CHANGE: 19980501 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-03-26 0 0001061027 Viracta Therapeutics, Inc. VIRX 0001849075 Rubino Stephen C/O VIRACTA THERAPEUTICS, INC. 2533 S COAST HWY 101, SUITE 210 CARDIFF CA 92007 1 0 0 0 Stock Option (Right to Buy) 8.74 2021-03-26 4 A 0 80000 0.00 A 2031-03-26 Common Stock 80000 80000 D One thirty-sixth (1/36th) of the Shares subject to the Option shall vest on the one (1) month anniversary of March 3, 2021 (the "Vesting Commencement Date"), and one thirty-sixth (1/36th) of the Shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Therapeutics, Inc. 2021 Equity Incentive Plan) through each such date. /s/ Michael Mueller, as Attorney-in-Fact 2021-03-30